GSK struck a $357 million agreement with French biotech Syndivia to access a preclinical antibody-drug conjugate (ADC) program for prostate cancer. The deal covers preclinical work and potential downstream milestones tied to development and commercialization. The pact follows recent conference attention on ADCs and reflects Big Pharma’s continued investment in targeted cytotoxic delivery for solid tumors. GSK’s dealbook approach leverages external innovation to populate oncology pipelines without bearing all early-stage risk. Observers will monitor preclinical-to-clinical transition timelines and whether the ADC differentiates on payload, linker stability, or target selection compared with competing prostate ADC programs.